[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016, 66(2):115-132.
[2] 邵国良. 血管生成与肝癌介入治疗[J].国外医学临床放射学分册,2000,23(1):22-25.
[3] 孙立春,Coy DH.受体靶向多肽抗肿瘤药物[J].上海医药, 2015,36(1):69-74.
[4] 张宁,张华.靶向给药系统研究进展[J].辽宁中医药大学学报,2017,19(2):218-221.
[5] 夏江华,冯军.多肽偶联药物的研究进展[J].世界临床药物,2014,35(9):556-559.
[6] 陈维翠,刘淑仪,林爱华,等.转铁蛋白标记磁性脂质体的制备及体外成像[J].中国组织工程研究,2017,21(6):923-927.
[7] 余琪琪,孟蕾,谭拥军.转录因子FoxMl—癌症治疗新靶点[J].分子诊断与治疗杂志,2011,3(5):339-343.
[8] 田宇航,刘钊,梁锡天,等.肝癌靶向治疗靶点的研究进展[J].现代肿瘤医学,2018,26(5):776-779.
[9] Wu CH, Liu IJ, Lu RM, et al.Advancement and applications of peptide phage display technology in biomedical science[J].J Biomed Sci,2016,23(1):1-14.
[10] Du B,Han H,Wang Z, et al.Targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide[J].Mol Cancer Res,2010,8(2):135-144.
[11] Du YZ,Cai LL,Liu P,et al.Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles[J].Biomaterials,2012,33(34):8858-8867.
[12] Liu N, Tan Y, Hu YW, et al. A54 peptide modified and redox-responsive glucolipid conjugate micelles for intracellular delivery of doxorubicin in hepatocarcinoma therapy[J].ACS Appl Mater Interfaces,2016,8(48):33148-33156.
[13] 孟娇,岳苗苗,韩红辉,等.肝癌特异性黏附肽A54体外靶向治疗研究[J].现代免疫学,2010,30(3):217-221.
[14] 岳苗苗. 肝癌特异性靶向药物A54-GFLG-DOX的制备及生物学活性鉴定[D].上海:华东师范大学,2011.
[15] Lo A,Lin CT, Wu HC.Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery[J]. Mol Cancer Ther,2008,7(3):579-589.
[16] Li YL,Hu Y, Xiao J, et al.Investigation of SP94 peptide as a specific probe for hepatocellular carcinoma imaging and therapy[J].Sci Rep,2016,6:33511.
[17] 李艳丽,肖杰,呼岩,等.SP94靶向肽在肝细胞肝癌显像中的应用[J].中华核医学与分子影像杂志,2017,37(1):10-14.
[18] 张红绪,曹静,周庆峰,等.蜂毒素-SP94杂合基因原核表达载体的构建及蛋白纯化[J].河南师范大学学报,2011, 39(3):122-125.
[19] Wu CH,Lan CH,Wu KL,et al.Hepatocellular carcinoma-targeted nanoparticles for cancer therapy[J].Int J Oncol, 2018,52(2):389-401.
[20] 邬怡然,毕振飞,黄家明,等.靶向FoxM1多肽P201对人肝癌HepG2细胞的杀伤作用及关键氨基酸分析[J].现代生物医学进展,2017,17(6):1024-1028.
[21] Wierstra I,Alves J.FOXM1, a typical proliferation-associated transcription factor[J]. Biol Chem,2007,388(12):1257-1274.
[22] 顾小文,朱从奎,张连美,等.肝细胞癌患者FOXM1的表达及临床意义[J].现代消化及介入治疗,2017,22(2):195-198.
[23] 刘文荣,丁若凡,张一鸣,等.抗肿瘤多肽9R-P201诱导下的肝癌HepG2细胞转录组测序分析[J].生物技术通报,2017,33(7):210-215.
[24] Bi Z,Liu W,Ding R,et al.A novel peptide,9R-P201,strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down- regulation of FoxM1 expression[J].Eur J Pharmacol,2017,796:175-189.
[25] Lee JH, Engler JA, Collawn JF, et al. Receptor-mediated uptake of peptides that bind the human transferrin receptor[J].Eur J Biochem,2001,268(7):2004-2012.
[26] Dai XY,Xiong YL,Xu DD,et al.TfR binding peptide screened by phage display technology-characterization to target cancer cells[J].Trop J Pharm Res,2014,13(3):331-338.
[27] 严秀云,丁伯美,胡青,等.T7肽修饰氧化还原敏感型聚酰胺-胺作为siRNA递送载体的初步评价[J].中国医药工业杂志,2018,49(6):767-773.
[28] Zheng Q, Xiong Y L, Su J Z, et al.Expression of curcin-transferrin receptor binding peptide fusion protein and its anti-tumor activity[J].Protein Expr Purif,2013,89(2):181-188.
[29] 杨璞,何剪太,王吉伟.噬菌体随机肽库筛选肝癌细胞特异性结合肽的实验研究[J].南方医科大学学报,2009,29(9): 1806-1808.
[30] 张旭,彭健,王顺伟,等.噬菌体随机肽库对肝癌细胞特异性结合短肽的筛选及鉴定[J].第四军医大学学报,2008, 29(17):1544-1547.
[31] Lee YL, Ahn BC, Lee Y, et al.Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand[J].J Pept Sci,2011,17(11):763-769.
[32] Fosgerau K, Hoffmann T.Peptide therapeutics: current status and future directions[J]. Drug Discovery Today,2015,20(1):122-128. |
